A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Study acronym: OSSIA
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 5
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Study sites: 1 to 3
    • Start date changed from estimate of Aug 17, 2026 to Sep 2, 2026
    v5
  3. Trial sites reduced: 11 → 1 locations
    • Eligibility criteria expanded, about 3 words
    v4
  4. Recruitment opened
    • Site details revised at 11 of 11 sites
    v3
  5. Start date: Jul 15, 2026 to Aug 17, 2026v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).
Trial Details
NCT Number NCT07609719
Lead Sponsor Genentech, Inc.
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov